Reuters logo
BRIEF-Lipocine validates “no titration” dosing regimen with positive topline efficacy results for LPCN 1021
June 19, 2017 / 8:19 PM / 5 months ago

BRIEF-Lipocine validates “no titration” dosing regimen with positive topline efficacy results for LPCN 1021

June 19 (Reuters) - Lipocine Inc:

* Lipocine validates “no titration” dosing regimen with positive topline efficacy results for lpcn 1021, oral testosterone candidate

* Lipocine Inc- LPCN 1021 achieved primary endpoints confirming efficacy of twice daily oral administration

* Lipocine Inc- LPCN 1021 generally met pre-specified per dose secondary endpoints for twice daily oral administration

* Lipocine Inc- new drug application resubmission planned in Q3 of 2017

* Lipocine Inc - all drug related adverse events (“AES”) were either mild or moderate in intensity and none were severe Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below